Topical Psoriasis Update: Today’s Topical Treatment Strategies to Optimize Patient Response and Quality of Life
Topical treatments for psoriasis have been the mainstay of treatment strategy, but their use has evolved and will be impacted with the emergence of biologic therapies. This program has been designed to provide an overview of the latest available therapies to help physicians understand the important role topical treatment will continue to play in the new age of biologics. This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration (FDA). Health Management Solutions, Inc, the Dannemiller Memorial Educational Foundation, and Warner Chilcott do not recommend the use of any agent outside of the labeled indications.
The FDA approved therapies for melanoma, dermatomyositis, superficial basal cell carcinoma, and adolescent alopecia areata, while TYK2 inhibitors and rare disease filings advanced toward 2027 decisions.
Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.